NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 2%

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) dropped 2% during mid-day trading on Tuesday . The company traded as low as $0.88 and last traded at $0.91. Approximately 28,681 shares were traded during trading, a decline of 87% from the average daily volume of 217,424 shares. The stock had previously closed at $0.93.

NeuroSense Therapeutics Price Performance

The company has a market capitalization of $12.50 million, a price-to-earnings ratio of -1.10 and a beta of 1.55. The firm has a fifty day simple moving average of $1.26 and a 200 day simple moving average of $1.26.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings results on Friday, April 5th. The company reported ($0.16) earnings per share (EPS) for the quarter.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.